MedTrace Logo

The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.

NCT04400760 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

Sodium GLucose Transport 2 inhibitors (SGLT2I), including dapagliflozin, reduce the likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of which the mechanism has not been fully elucidated. The mechanistic effects of dapagliflozin on platelet function profiles have not yet been ascertained. It remains unclear if this reduction in cardiovascular death is mediated by decreased platelet reactivity.

Conditions

  • Platelet Dysfunction

Interventions

DRUG

DAPA Tx

The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.

Sponsors & Collaborators

  • The University of The West Indies

    lead OTHER

Principal Investigators

  • Naveen A Seecheran, MBBS MSc · The University of The West Indies

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • Trinidad and Tobago

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04400760 on ClinicalTrials.gov